FDMT · NASDAQ · Biological Products, (No Diagnostic Substances)
Biological Products, (No Diagnostic Substances) company based in Emeryville, Ca.
In the last 90 days, no insider of 4d Molecular Therapeutics reported an open-market purchase and 0 open-market sales. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 6, 2026
$12.56
Last 12 months
Not enough history
Market value
Not available
Bets against the stock: 12M shares sold short, −0.5% vs the previous count, 18.6 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$3.78M
+25106.7% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net cash
$50.8M
Debt $19.6M, cash $70.4M, at Jun 30, 2026
Net income, last 12 months
−$179M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 13, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Traded Oct 5 · filed the same day
A 4d Molecular Therapeutics officer told the SEC about a plan to sell $754K of 4d Molecular Therapeutics shares around Oct 5, 2026. The shares were not acquired as compensation. That is 0.1% of all 4d Molecular Therapeutics shares.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Top officer leaving
“Departure of President and Chief Operating Officer On December 31, 2025, in connection with his transition to a new part-time employment position, Fariborz Kamal, Ph.D., resigned as President and Chief Operating Officer of the Company effective immediately to pursue other opportunities.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
2 active phase 3 trials and 6 active phase 2 trials led by this company, mostly in fabry disease, x-linked retinitis pigmentosa, neovascular (wet) age-related macular degeneration. The ones with the nearest registered primary completion date still ahead:
3 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.